A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma

NCT02706782 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: TAI-meso-CART

Sponsor

Shanghai GeneChem Co., Ltd.